- Non-dilutive growth financing of up to 50 million US dollarswith synthetic royalty functionality and availability linked to reaching certain sales milestones
- Proceeds from the financing will fund the expansion of Motiva® devices by Human Investments Ltd. Asia
- Transaction highlights R-Bridge’s commitment to supporting access to innovative, high-quality and safe healthcare solutions
SINGAPORE, December 12, 2024 /PRNewswire/ — R-Bridge Healthcare Fund (“R-Bridge”), a subsidiary of the CBC Group, Asia the largest dedicated healthcare asset management company, today announced the closing of a non-dilutive growth financing facility of up to 50 million US dollars for Human Investments Ltd.
Human Investments Ltd., through its subsidiaries Motiva Korea and Motiva China, is the exclusive distribution partner in Korea and China for Etablissement Labs Holdings Inc.’s innovative femtech solutions in the areas of breast health, breast aesthetics and breast reconstruction. The transaction allows Human Investments Ltd. to access non-dilutive growth financing of up to 50 million US dollarswith synthetic royalty functionality and availability linked to reaching certain sales milestones. The proceeds will support Motiva Korea’s continued growth and leadership position in the Korean medical aesthetics and reconstruction market. Additionally, it will fund Motiva China’s market expansion, following National Medical Products Administration (NMPA) approval of Establishment Labs in November 2023 for the sale of Motiva® devices in China.
Dr Michael Keyoung, Senior Managing Director and Head of Private Credit and Royalties at CBC Groupsaid: “R-Bridge is pleased to partner with Human Investments Ltd. to support the commercial launch in Asia of its innovative and differentiated solutions. We are impressed by the success of Human Investments Ltd. in establishing market leadership as the world reference in Korean aesthetic medicine. and reconstruction. This funding demonstrates our commitment to supporting promising healthcare companies by expanding access to innovative, high-quality and safe solutions aimed at improving health and well-being.
John Limfounder and CEO of Human Investments Ltd.said: “Three years after launching in Korea, we created Motiva® as the preferred brand and market leader in augmentation and reconstructive mammaplasty in the Korean women’s health market, and we plan to replicate this success through Asia. Surgeons and consumers are highly responsive to the latest scientific and technological innovations, and we are excited about the opportunities this funding will provide for Human Investments Ltd. to position Motiva® as a truly innovative and differentiated option in the Asian medical aesthetics and reconstruction market. “
About R-Bridge
R-Bridge Healthcare Fund is a subsidiary of the CBC Group, Asia largest asset management company dedicated to healthcare with assets under management of 9 billion dollarswhose headquarters are at Singapore with offices in the United States, AsiaAnd Europe. Through a diversified, multi-product strategy, CBC Group focuses on platform creation, buyout, private credit and royalties, as well as real estate, in the healthcare space, including pharmaceutical, biotechnology, medical and health.
R-Bridge was founded in 2019 to provide alternative, non-dilutive financing to healthcare companies, supported by royalties, interest on revenues and other cash flows generated from sales of healthcare products and services in Asia as well as globally, with the aim of generating attractive, uncorrelated returns for investors. R-Bridge raised its inaugural fund in 2020 and is currently investing from its successor fund, RBF II.
For more information, please visit www.cbridgecap.com
Connect with us on LinkedIn (Radio-Canada Group).
About Human Investments Ltd.
Based in the United Arab EmiratesHuman Investments Ltd. is the exclusive distribution partner in Korea and China for Establishment Labs Holdings Inc., a global medical technology company dedicated to improving the health and well-being of women through the power of science, engineering and technology. Through its subsidiaries Motiva Korea and Motiva China, Human Investments Ltd. currently markets Motiva® devices in Korea and China markets. Motiva® devices, known for their advanced 3D negative printing technology, are recognized for their superior security and natural look and feel. The Motiva Flora® Tissue Expander is used to improve the outcomes of breast reconstruction after breast cancer and is the world’s only regulatory expander with an integrated port using MRI-conditional radiofrequency technology. Since their first commercialization in 2010, nearly four million Motiva® devices have been delivered to plastic and reconstructive surgeons in the more than 85 countries in which they are available. The Motiva® device recently received US FDA approval, representing the first new PMA breast implant approved by the US FDA since 2013. Following regulatory approval from the National Medical Products Administration (NMPA) in November 2023Motiva® devices were launched in February 2024 In Chinaleveraging its leading position in the Korean market.
Show original content:https://www.prnewswire.com/apac/news-releases/cbc-group-r-bridge-healthcare-fund-announces-up-to-us50-million-financing-for-human-investments-ltd-to- motiva-fund-market-expansion-302329799.html
SOURCE CBC Group
